Tilavonemab

Tilavonemab (ABBV-8E12) is a humanized anti-tau monoclonal antibody that binds to amino acids 25-30 near the N-terminus of the tau protein. Tilavonemab can block the ability of human and mouse neurons to uptake tau aggregates. Tilavonemab can be used for research on Alzheimer’s disease and other tauopathies[1][2][3].

Product Specifications

CAS Number

[2096513-89-0]

Product Name Alternative

ABBV-8E12; C2N-8E12

UNSPSC

12352203

Target

Tau Protein

Type

Inhibitory Antibodies

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/tilavonemab.html

Purity

99.59

Solubility

10 mM in DMSO

Smiles

[Tilavonemab]

Molecular Weight

(145 kDa)

References & Citations

[1]Vaswani P A, et al. Immunotherapy in progressive supranuclear palsy. Curr Opin Neurol. 2020 Aug;33 (4) :527-533. |[2]Lopez-Cuina M, et al. Targeting alpha-synuclein or tau for treating neurodegenerative movement disorders[J]. Revue Neurologique, 2022, 178 (5) : 460-471.|[3]Neațu M, et al. Monoclonal antibody therapy in Alzheimer’s disease[J]. Pharmaceutics, 2023, 16 (1) : 60.